What to expect from 2018

We are really excited to announce that represented on this year’s program include some of the most foremost and innovative medical device manufacturing companies within the industry; including Abbott, Boston Scientific, Cardinal Health and CR Bard.

Across the two days, top senior-level representatives and decision makers will come together to discuss some of the most pressing challenges, objections and practical steps the sector can take towards outsourcing clinical studies. Further to this, presentation will be given from both incumbent and new entrant companies, to provide a wide scope of expertise and lessons learnt from experience.

Day one will focus on industry trends and regulatory changes from few different perspectives considering the market situation. You will find sessions highlighting changed requirements of the MDR and usage of new database EUDAMED and what to prepare to enable smooth trial.  

Throughout the second day, we will focus on outsourcing strategies and offer deeper insight on how much to outsource and what to outsource, how to find your CRO especially in SME perspectives with a case study. Furthermore, you will have an opportunity to further discussion on strategies to take the best benefit of working with CROs on round table.